Law360, New York (July 07, 2009) -- Genzyme Corp. has targeted Sandoz Inc, the generics arm of Novartis AG, in its latest effort to keep a generic version of Renagel off the market before the expiration of its patent for the well-known kidney treatment.
The Cambridge, Mass.-based drugmaker filed suit Thursday in the U.S. District Court for the District of Maryland over U.S. Patent Number 5,667,775, which covers both Renagel and Renvela, a second-generation...
